$Eyenovia(EYEN)$ 【Main business fails, keeps crypto trading alive—has Eyenovia lost its mind?】

Can’t make it in eye drops? Then just “buy crypto to survive”—this isn’t a joke. It’s a real story from Nasdaq.

Eyenovia suddenly announced a $50 million financing, going all-in on the Hyperliquid (HYPE) token, and is even planning to change its name to “Hyperion DeFi.” The company originally made ophthalmic medical devices, but last year its new drug failed, and it laid off half its workforce—so now it has completely pivoted to become a “blockchain validation node.” The moment the announcement came out, the stock surged by more than 130%, only to plunge a few hours later; and before yesterday’s pre-market trading, it dropped another 10%. The hype didn’t even last 24 hours before it turned around and dragged things back to how they originally looked.

Even more surreal: this money wasn’t made—it was raised through convertible bonds plus share warrants. In other words, existing shareholders were diluted clearly and transparently, just so the company could go on a high-stakes gamble with a pile of virtual tokens. Meanwhile, the “boosted” HYPE itself fell 6% on the day.

Biotech companies don’t properly do R&D—they fixate on hot crypto cash. Does this plot feel a little familiar? MicroStrategy has played Bitcoin to a whole new level, and now a bunch of fringe companies can’t learn the essence—they only copy the surface-level excitement.

#hype